Better matching cancer patients to their best treatments
Official title: BIOCLIN: A precision medicine platform to support biomarker-driven clinical trials
Funded at Vindhya Data Science INC. · NIH-11132957 · Data updated 2026-11-12
This project is developing a new software tool to help doctors choose the most effective cancer treatments, especially immunotherapies, for patients based on their unique genetic information.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vindhya Data Science INC. NIH-funded |
| Lab location | 1 site (Morrisville, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $174,107 |
| NIH project number | 5R43TR005143-02 |
| Project ID | NIH-11132957 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is most relevant for cancer patients who may be candidates for biomarker-driven therapies, especially immunotherapies.
✕Less likely to help
Patients whose cancer treatment decisions are not currently guided by genetic biomarkers or who are not candidates for advanced therapies like immunotherapy may not directly benefit from this specific platform.
What this research studies
Currently, doctors often use DNA mutations to decide which cancer treatments might work best. However, for some therapies like immunotherapy, these mutations don't always predict who will respond well. This project explores using RNA sequencing, a more detailed genetic test, which has shown promise in preclinical studies for better predicting treatment success. We are building a special software called BIOCLIN to analyze this RNA sequencing data and help doctors make more precise treatment decisions for cancer patients.
Why it matters
Potential benefit: If successful, this work could lead to more effective and personalized treatment plans for cancer patients, particularly those receiving immunotherapy.
How similar studies have gone: RNA sequencing has shown improved accuracy over mutations in preclinical studies, and a prototype of this software is already being used in an ongoing kidney cancer trial.
Where this research is happening
-
Vindhya Data Science INC.
Morrisville, United States Active
Researchers
- Principal investigator: Reddy, Anupama — Vindhya Data Science INC.
- Study coordinator: Reddy, Anupama
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.